4DMedical (ASX:4DX) ROCE %: -299.91% (As of Dec. 2025)


ASX:4DX 4DMedical Ltd ASX:4DX
64 GF Score
Price A$4.16
GF Value A$1.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical ROCE %?

4DMedical ASX:4DX -8.97% 64 ROCE % is -299.91% as of Dec. 2025. GuruFocus rates ASX:4DX with a GF Score™ of 64/100 and a GF Value™ of A$1.44 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 4DMedical's annualized ROCE % for the quarter that ended in Dec. 2025 was -299.91%.

4DMedical  (ASX:4DX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

4DMedical ROCE % Related Terms

4DMedical ROCE % Historical Data

* Premium members only.

The historical data trend for 4DMedical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4DMedical ROCE % Chart

4DMedical Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial -51.10 -47.94 -43.07 -41.61 -34.98

4DMedical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.51 -39.42 -43.07 -28.59 -299.91
ASX:4DX
64GF Score
4DMedical Ltd ASX:4DX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4DMedical ROCE % Calculation

4DMedical's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-30.148/( ( (121.713 - 24.884) + (94.812 - 19.255) )/ 2 )
=-30.148/( (96.829+75.557)/ 2 )
=-30.148/86.193
=-34.98 %

4DMedical's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-308.064/( ( (94.812 - 19.255) + (139.549 - 9.668) )/ 2 )
=-308.064/( ( 75.557 + 129.881 )/ 2 )
=-308.064/102.719
=-299.91 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -299.91% mean?
4DMedical (ASX:4DX) has a ROCE % of -299.91% as of Dec. 2025.
Is 4DMedical's ROCE % too high?
4DMedical's current ROCE % is -299.91%. Overall, 4DMedical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's ROCE % compare to ABT and SYK?
4DMedical's ROCE % of -299.91% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4DMedical's current ROCE % is -299.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (ASX:4DX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$1.44, compared to a current price of A$4.16 — trading 188.9% above its estimated fair value. The current ROCE % is -299.91%. 4DMedical's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For 4DMedical (ASX:4DX), the current ROCE % is -299.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4DMedical (ASX:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of A$4.16 is trading 188.9% above its estimated GF Value™ of A$1.44. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for ASX:4DX:

  • ROCE %: -299.91%
  • GF Value™: A$1.44 vs. price of A$4.16 (188.9% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ASX:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4DMedical Business Description

Other Exchanges FDMDF:USAMQ7:Germany
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
64GF Score

Get the complete analysis for ASX:4DX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.16
Price
A$1.44
GF Value